TULSA Abstracts at the 15th Interventional MRI Symposium Strengthen Real-World Evidence, Clinical Differentiation, and Platform Expansion Opportunity
Profound Medical announced five abstracts at the 15th Interventional MRI Symposium supporting the real-world performance and clinical differentiation of its TULSA-PRO system. The randomized CAPTAIN trial showed whole-gland TULSA was statistically superior to robotic radical prostatectomy at six months, with patients more than twice as likely to preserve both erectile function and pad-free continence (risk ratio 2.1, p=0.004).
Key figures
- Drug Name
- TULSA-PRO
- Phase Of Trial
- CAPTAIN randomized controlled trial, six-month functional endpoint
- Mayo florida patients
- 58
- Care registry patients
- 197
- Mayo rochester patients
- 41
- Low field targeting accuracy
- 1.0 ± 0.9 mm
- Mayo rochester psa reduction
- approximately 62%-66% through one year
- Mayo florida pad free continence
- 100%
- Thermometry precision improvement
- 40%
- Captain hospitalizations complications
- 0.7% TULSA vs 6.3% robotic RP
- Captain erectile contincence risk ratio
- 2.1 (p=0.004)
AI analysis
Red flags3 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.